We are live on ! Find out more
MAM

MPM Asset Management Portfolio holdings

AUM $44.5M Turnover 20%
1-Year Est. Return 47.28%
This Fund
S&P 500
This Quarter Est. Return
+26.88%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$226M
AUM Growth
–
Cap. Flow
+$205M
Cap. Flow %
90.78%
Top 10 Hldgs %
100%
Holding
10
New
10
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 years
Top 10 Avg Time Held
0 years
Top 20 Avg Time Held
0 years

Top Buys

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$74M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$48.5M
3
PCRX icon
Pacira BioSciences
PCRX
+$23.8M
4
VSTM icon
Verastem
VSTM
+$17.4M
5
KBIO
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
+$14.9M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 92.02%
2 Miscellaneous 7.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
EPZM
1
DELISTED
Epizyme, Inc
EPZM
$81M 35.87%
+2,880,485
New +$74M
2013 Q2
0 quarters
PTLA
2
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$60M 26.55%
+2,441,344
New +$48.5M
2013 Q2
0 quarters
VSTM icon
3
Verastem
VSTM
$734M
$24.1M 10.67%
+144,681
New +$17.4M
2013 Q2
0 quarters
PCRX icon
4
Pacira BioSciences
PCRX
$1.46B
$23.9M 10.58%
+824,255
New +$23.8M
2013 Q2
0 quarters
KBIO
5
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$14.9M 6.6%
+329,116
New +$14.9M
2013 Q2
0 quarters
ALT icon
6
Altimmune
ALT
$453M
$10.1M 4.47%
+21,159
New +$10.5M
2013 Q2
0 quarters
AVEO
7
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$5.52M 2.44%
+220,896
New +$9.44M
2013 Q2
0 quarters
ZLCS
8
DELISTED
ZALICUS INC COM NEW
ZLCS
$3.12M 1.38%
+927,830
New +$3.32M
2013 Q2
0 quarters
ETRM
9
DELISTED
EnteroMedics Inc.
ETRM
$1.9M 0.84%
+1,590
New +$1.68M
2013 Q2
0 quarters
PETX
10
DELISTED
Aratana Therapeutics, Inc.
PETX
$1.36M 0.6%
+180,505
New +$1.43M
2013 Q2
0 quarters

Similar funds

WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

MPM Asset Management's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for MPM Asset Management, which disclosed 10 positions worth $226M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Epizyme, Inc: 2,880,485 shares worth $81M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, followed by Miscellaneous.

  • MPM Asset Management's largest Q2 2013 buy was Epizyme, Inc: 2,880,485 shares worth $81M.
  • MPM Asset Management's ten largest holdings make up 100% of its $226M portfolio in Q2 2013.
  • MPM Asset Management disclosed 10 positions in Q2 2013, its first 13F filing on record.

Based on MPM Asset Management's 13F filing for Q2 2013, filed 8 Aug 2013.